Sanford Health, the large provider organization for rural health care, announced an $800,000 investment in TruGenomix, a veteran-owned precision behavioral health company. As part of the strategic partnership, Sanford Health will support TruGenomix by providing its state-of-the-art lab and research capabilities to validate a first-to-market patented blood test for post-traumatic stress disorder (PTSD).
Sanford Imagenetics will sequence 2,000 samples using TruGen-1, a laboratory-developed blood test (LDT), which is based on decades of research culminating in a patent for gene expression biomarker profiles that identify an individual’s risk of developing PTSD. These biomarkers were discovered and validated using blood samples from a diverse population of individuals who have experienced extreme trauma, including 9/11 first responders, military service members, sexual assault survivors, and Holocaust survivors and their descendants. Sanford Health and TruGenomix also will pursue contract and development opportunities in the genetic-testing field.
Sanford Health, a large health system in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South Dakota, the organization includes 44 hospitals, 1,400 physicians, and more than 200 Good Samaritan Society senior care locations in 26 states and nine countries.
TruGenomix is a behavioral health care company. Their mission is to save lives, reduce suffering, and eradicate stigma from post-traumatic stress disorder (PTSD) through earlier and more effective diagnosis and treatment of PTSD and other behavioral health disorders.
This was reported by PR Newswire on July 23, 2020.
Contact information: Jen Williams, Executive Media Consultant, TruGenomix, 155 Gibbs Street, #559, Rockville, Maryland 20850; 802-355-5072; Email: email@example.com; Website: https://trugenomix.com/